Supplementary materials: Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer

<b>These are peer-reviewed supplementary materials for the article '</b><b>Indirect treatment comparison of </b><b>lurbinectedin versus other second-line </b><b>treatments for small-cell lung cancer</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Table S1: </b>Eligibility criteria for screening<b>Table S2: </b>Search strategy for Embase<b>Table S3: </b>Search strategy for MEDLINE<b>Table S4: </b>Search strategy for Cochrane Register of Controlled Trials<b>Table S5: </b>Summary of absolute standardized difference and effective sample size when matched to the basket trial platinum-sensitive subgroup (n = 60)<b>Table S6: </b>Estimated odds ratios and hazard ratios for overall survival and overall response rate across sensitivity analyses<b>Table S7: </b>Estimated odds ratios from the fixed-effect network meta-analysis of hematological adverse events<b>Figure S1: </b>Network of trials included in the feasibility assessment, with visualization of platinum sensitivity status<b>Figure S2: </b>Evidence networks for overall response rate, overall survival, grade 3/4 anemia, grade 3/4 thrombocytopenia, and grade 3/4 neutropenia for <b>(A)</b> sensitivity analysis #1 and <b>(B)</b> sensitivity analysis #2<b>Figure S3:</b> Results from network meta-analysis of progression-free survival/time to progression. <b>Aim: </b>Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. <b>Methods:</b> An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. <b>Results:</b> In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). <b>Conclusion:</b> Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC.